Clinical Trials Logo

Children;Infection clinical trials

View clinical trials related to Children;Infection.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03643497 Recruiting - Children;Infection Clinical Trials

Population Pharmacokinetics of Meropenem and Linezolid in Children With Severe Infectious Diseases

Start date: July 1, 2018
Phase:
Study type: Observational [Patient Registry]

This study is based on the hypothesis that the pharmacokinetics of meropenem and linezolid in severe infectious children are different from mild infectious children and adults. The investigators aim to study the population pharmacokinetics of children receiving the meropenem and linezolid for treatment of severe infectious diseases. In this study, the investigators will detect drug concentration in plasma and cerebrospinal fluid by using residual blood samples of blood and cerebrospinal fluid gas analysis and other clinical tests and employ computers for constructing population pharmacokinetic models. In addition, the investigators also want to correlate use of meropenem and linezolid with treatment effectiveness and incidence of adverse effects in children. This novel knowledge will allow better and more rational approaches to the treatment of severe infectious diseases in children. It will also set the foundation for further studies to improve anti- infective drug therapies for severe infectious children.

NCT ID: NCT03113344 Recruiting - Children; Infection Clinical Trials

Population Pharmacokinetics of Anti-infective Drugs in Children With Infectious Diseases

Start date: June 21, 2017
Phase: N/A
Study type: Observational [Patient Registry]

This study is based on the hypothesis that the pharmacokinetics of anti-infective drugs in children are different from adults. We aim to study the population pharmacokinetics of children receiving the anti-infective drugs for treatment of infectious diseases. In this study, we will detect drug concentration in plasma by using residual blood samples of blood gas analysis and other clinical tests and employ computers for constructing population pharmacokinetic models. In addition, we also want to correlate use of anti-infective drugs with treatment effectiveness and incidence of adverse effects in children. This novel knowledge will allow better and more rational approaches to the treatment of infectious diseases in children. It will also set the foundation for further studies to improve anti-infective drug therapies for children.